Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
2 participants
OBSERVATIONAL
2007-10-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at fentanyl in patients with cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
NCT00516269
Pharmacokinetics of Dactinomycin in Young Patients With Cancer
NCT00900354
Analyses of Human Samples Collected in Clinical Trials
NCT00339664
Fenretinide in Treating Patients With Solid Tumors
NCT00003250
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
NCT04188418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate in adult patients with cancer.
OUTLINE: Patients undergo blood sample collection before and after discontinuation of fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
receiving fentaly citrate
fentanyl citrate
pharmacological study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fentanyl citrate
pharmacological study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of cancer
* Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days
PATIENT CHARACTERISTICS:
* Willing to change to an alternative opioid
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 72 hours since transdermal fentanyl citrate administration
* At least 12 hours since transmucosal fentanyl citrate administration
* No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stuart A. Grossman, MD
Role: PRINCIPAL_INVESTIGATOR
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JHOC-J06129
Identifier Type: -
Identifier Source: secondary_id
JHOC-NA-00006329
Identifier Type: -
Identifier Source: secondary_id
J06129 CDR0000600337
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.